Page last updated: 2024-08-16
sb 202190 and olaparib
sb 202190 has been researched along with olaparib in 2 studies
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Chen, X; Chen, Y; Hou, X; Lin, X; Su, S; Tian, Y; Zhang, Q | 1 |
Other Studies
2 other study(ies) available for sb 202190 and olaparib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
The Drug Combination of SB202190 and SP600125 Significantly Inhibit the Growth and Metastasis of Olaparib-resistant Ovarian Cancer Cell.
Topics: Animals; Anthracenes; Autophagy; Cell Line, Tumor; Cell Proliferation; Drug Combinations; Female; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; Mice; Ovarian Neoplasms; p38 Mitogen-Activated Protein Kinases; Phthalazines; Piperazines; Protein Kinase Inhibitors; Pyridines | 2018 |